Phase I /II and Pharmacological Clinical Study of Combination Chemotherapy with Irinotecan(CPT-11) and Erlotinib(Tarceva) for Recurrent Lung Cancer
Phase 1
- Conditions
- recurrent non small cell lung cancer after chemotherapy
- Registration Number
- JPRN-UMIN000004639
- Lead Sponsor
- Shimane university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
Active infection. Severe DM. Severe heart disease, angina, myocadial infarction before 3 month. Active peptic ulcer. Concomitant malignancy. Severe neural disease. Severe comorbidity. Interstitial pneumonia in chest CT. Symptomatic brain metastasis. Severe ascites. Severe pleural effusion. Severe pericardial effusion. Impaired blodd coagulation. Pregnant, potential pregnant, or lactating. Severe drug hypersensitivity. Judged inappropriate for the trial by the doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method progression free survival, safety, QO